BioPortfolio - Phase II Myogane
Phase II Myogane - BioPortfolio. ... BioPortfolio - Phase II Myogane Cogane™ is in clinical development as a treatment for Parkinson’s ... Myogane. ...
http://www.bioportfolio.com/search/Phase_II_Myogane.html...
|
Myogane™ - Phytopharm plc
Myogane™ also reverses the decrease of neuronal growth factors, reverses oxidative and glutamate damage ... Track designation to Myogane™ for the
treatment ...
http://www.phytopharm.com/portfolio/?id=2142...
|
BioPortfolio - Phytopharm Plc
Full confidential disclosure of the substantial data sets for both Cogane™ and Myogane™, our lead products for Alzheimer’s and motor neurone disease, ...
http://www.bioportfolio.com/biocorporate/28354-Phytopharm_Pl...
|
Myogane granted European Union Orphan Medicinal Product ...
The Orphan Medicinal Product Designation provides Phytopharm with market exclusivity in the European Union for 10 years following Myogane™’s market ...
http://www.phytopharm.com/news/newsreleases/?id=8361...
|
Natural Products in Drug Discovery and Development Alan Harvey
(Myogane), for the treatment of neurodegenerative disease. Introduction. Natural products for drug discovery: awesome or awful? ...
http://www.biomedcentral.com/content/pdf/cd-619165.pdf...
|
Commencement of Phase Ib clinical study for Myogane™ - Phytopharm plc
Myogane ™ is a novel orally active neurotrophic factor inducer being developed for amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), ...
http://www.phytopharm.com/news/newsreleases/?page=2&id=5129...
|
Natural Products in Drug Discovery and Development...[IDrugs. 2005 ...
... and two compounds in development by Phytopharm plc, PYM-50028 (Cogane) and PYM-50018 (Myogane), for the treatment of neurodegenerative disease. ...
http://www.ncbi.nlm.nih.gov/pubmed/16118691...
|
Interim Management Statement for 3 months ended 30 June 2008 ...
30 Jun 2008 ... Myogane™. ·EU orphan medicinal product status granted by EMEA for ... Our pharmaceutical products Cogane™ and Myogane™ continue to make good ...
http://www.phytopharm.com/news/newsreleases/?id=8488...
|
Patent News Peter Steele * & Matthew Sparrowhawk
PYM-50018, also known as Myogane™, is a. neuroprotective and neuroregenerative compound that is. effective against the symptoms of ALS. ...
http://www.biomedcentral.com/content/pdf/cd-579696.pdf...
|
News Releases - Phytopharm plc
Myogane granted European Union Orphan Medicinal Product Designation for ALS. 21 May 2008. Phytopharm plc (PYM: London Stock Exchange) (“Phytopharm” or the ...
http://www.phytopharm.com/news/newsreleases/...
|
